• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Medicine >Serum Levels of T Cell Immunoglobulin and Mucin-Domain Containing Molecule 3 in Patients with Systemic Lupus Erythematosus
【24h】

Serum Levels of T Cell Immunoglobulin and Mucin-Domain Containing Molecule 3 in Patients with Systemic Lupus Erythematosus

机译：血清水平的T细胞免疫球蛋白和粘液结构域的Systemic Lupus红斑狼疮患者

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: T cell immunoglobulin and mucin-domain-containing molecule 3 (TIM-3) is implicated in the development of various autoimmune diseases. We aimed to investigate the levels of soluble TIM-3 (sTIM-3) and their associations between clinical parameters in patients with systemic lupus erythematosus (SLE). Methods: Serum samples were collected from 65 patients with SLE and 35 age-matched healthy controls (HCs). The SLE Disease Activity Index 2000 (SLEDAI-2K) and the Systemic Lupus International Collaborating Clinics (SLICC) damage index (SDI) were used to assess SLE disease activity and SLE-related organ damage. British Isles Lupus Assessment Group (BILAG)-2004 index was also used to assess SLE disease activity. Soluble TIM-3 (sTIM-3) in sera from patients with SLE and HCs were evaluated by enzyme-linked immunosorbent assay (ELISA). The results were compared with the clinical parameters of SLE including SLE disease activity. Results: Serum sTIM-3 levels in patients with SLE (median 2123 pg/mL (interquartile range (IQR), 229–7235)) were significantly higher than those in HCs (1363 pg/mL; IQR, 1097–1673; p = 0.0015). Serum levels of sTIM-3 were correlated with disease activity of SLE using the SLEDAI-2K score ( p 0.001, r = 0.53). The serum sTIM-3 levels in SLE patients with active renal disease (BILAG renal index A-B) were significantly higher than those without the active renal disease (BILAG renal index C–E). However, no significant difference was observed in serum sTIM-3 levels between SLE patients with and without active involvement in other organs (BILAG index). Serum sTIM-3 levels were significantly elevated in SLE patients with organ damage (2710 pg/mL; IQR, 256–7235) compared to those without organ damage (1532 pg/mL; IQR, 228–5274), as assessed by the SDI ( p = 0.0102). Conclusions: Circulating sTIM-3 levels are elevated in SLE patients, and serum sTIM-3 levels are associated with SLE disease activity and SLE-related organ damage. The data indicate a possible link between the TIM-3/Gal-9 pathway and SLE clinical phenotypes, and further investigation of the TIM-3 pathway in SLE pathophysiology is warranted.
机译：目的：T细胞免疫球蛋白和含粘蛋白 - 结构域的分子3（TIM-3）涉及各种自身免疫疾病的发展。我们旨在探讨可溶性Tim-3（SIT-3）的水平及其患有全身狼疮红斑狼疮（SLE）患者临床参数的关联。方法：从65例SLE和35岁匹配的健康对照（HCS）收集血清样品。 SLE疾病活动指数2000（SLEDAI-2K）和系统性狼疮国际合作诊所（SDI）损伤指数（SDI）用于评估SLE疾病活动和SLE相关的器官损伤。英国岛卢布评估组（Bilag）-2004指数也用于评估SLE疾病活动。通过酶联免疫吸附试验（ELISA）评估来自SLE和HCS患者的SERA中的可溶性TIM-3（STIM-3）。将结果与SLE临床参数进行比较，包括SLE疾病活动。结果：SLE患者血清STIM-3水平（中位数2123pg / ml（IQRILE范围（IQR），229-7235）显着高于HCs（1363 pg / ml; IQR，1097-1673; P = 0.0015）。使用SLEDAI-2K评分（P <0.001，R = 0.53）与SLE的SLE疾病活性相关的血清STAM-3水平。 SLUM患者的血清STIM-3水平为活跃的肾脏疾病（BILAG肾脏指数A-B）明显高于没有活性肾脏疾病（双老肾指数C-E）的患者。然而，在SLU患者之间的血清STIM-3水平中没有显着差异，没有积极参与其他器官（BILAG指数）。与没有器官损伤的人（1532 pg / ml; IQR，228-5274），SLUM患者（2710 pg / ml; IQR，256-7235）的SLUM STIM-3水平显着升高（p = 0.0102）。结论：SLE患者循环STIM-3水平升高，血清STIM-3水平与SLE疾病活动和SLE相关器官损伤有关。数据表明TIM-3 / GAL-9途径和SLE临床表型之间的可能链接，并有必要进一步研究SLE病理生理学中的TIM-3途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号